SCHEMBL13610341

SCHEMBL13610341

Fc1ccc(CSSSCc2ccccn2)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.45
KCNA5 P22460 1/20 0.45
LMNA P02545 1/20 0.44
NPC1 O15118 5/20 0.44
SMN1; SMN2 Q16637 4/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
ATM Q13315 1/20 0.42
KDM4E B2RXH2 1/20 0.40
MAPT P10636 1/20 0.40
TP53 P04637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40
TSHR P16473 1/20 0.40
TERT O14746 1/20 0.39
PKM P14618 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2591473 0.83 ALDH1A1 (0.49) RAB9AKCNA5LMNANPC1SMN1; SMN2
SCHEMBL19940286 0.83 MAPT (0.41) RAB9ALMNANPC1SMN1; SMN2L3MBTL1
SCHEMBL13610296 0.80 ALDH1A1 (0.51) RAB9ALMNANPC1SMN1; SMN2MAPT
SCHEMBL13610373 0.80 MEN1 (0.45) KCNA5LMNAMAPTMEN1KMT2A
SCHEMBL13610340 0.79 TERT (0.48) RAB9ANPC1SMN1; SMN2L3MBTL1KDM4E
SCHEMBL13610342 0.79 NPC1 (0.36) RAB9ANPC1SMN1; SMN2L3MBTL1ATM
SCHEMBL1740610 0.78 IDO1 (0.50) RAB9ANPC1TP53NPSR1ALDH1A1
SCHEMBL13780226 0.78 SMN1; SMN2 (0.47) RAB9ALMNANPC1SMN1; SMN2KDM4E
SCHEMBL13610358 0.77 MAPK1 (0.42) RAB9ANPC1SMN1; SMN2L3MBTL1ATM
SCHEMBL11445226 0.76 SMN1; SMN2 (0.57) RAB9ALMNANPC1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742635-B1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES INC (US) 2018-03-07 EP disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-8334316-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES, INC. (US) 2012-12-18 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-7622507-B2 Substituted organosulfur compounds and methods of using thereof ACEA BIOSCIENCES INC. (US) 2009-11-24 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF ACEA BIOSCIENCES, INC. (US) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090192146-A1 SUBSTITUTED ORGANOSULFUR COMPOUNDS AND METHODS OF USING THEREOF TST, CTH, CBS RAB9A 4609/4885KCNA5 3817/4885LMNA 4409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.